European Commission approves Roche’s Gavreto (pralsetinib) for the treatment of adults with RET fusion-positive advanced non-small cell lung cancer

NEXT STORY
The Global Human Combination Vaccines Market is expected to grow by $ 7.16 bn during 2021-2025, progressing at a CAGR of almost 9% during the forecast period
PREV STORY
22nd Century Group Announces CFO Transition
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

CBT Pharmaceuticals Initiates the APOLLO Oncology Clinical Trials Program

First Patient Dosed in Initial Immunotherapy Combination Trial Utilizing CBT’s Proprietary AssetsPLEASANTON, Calif. and ...

author_avatar
NASDAQ Market News

Myriad Announces Closing of Counsyl Acquisition

Transformational Acquisition Enhances Myriad’s Leadership Position in Women’s HealthSALT LAKE CITY, July 31, 2018 ...

author_avatar
NASDAQ Market News

Cancer Genetics, Inc. to Present at 28th Annual ROTH Conference on March 16, 2016

RUTHERFORD, N.J., March 14, 2016 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX), an emerging ...

author_avatar
NASDAQ Market News